Daratumumab Decreased Progression Risk in High-Risk Smoldering MM
Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.
Related Articles
Durvalumab Plus BCG Boosts DFS in Non–Muscle-Invasive Bladder Cancer
Durvalumab added to BCG induction and maintenance improved disease-free survival vs BCG alone in high-risk non–muscle-invasive bladder cancer.
Panitumumab Improves Outcomes in RAS/BRAF Wildtype Colon Cancer
Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.
Pembrolizumab Combo Improves PFS in Platinum-Resistant Ovarian Cancer
KEYNOTE-B96 showed pembrolizumab-based therapy improved PFS and OS in PD-L1–positive platinum-resistant ovarian cancer.
Best Practices in Managing Talquetamab-Associated AEs in Myeloma
A nurse practitioner gives her advice for managing adverse events during treatment with talquetamab for multiple myeloma.
Allogeneic CT0596 Shows Early Activity, Safety in R/R Myeloma
CT0596 was well tolerated and showed preliminary efficacy in relapsed/refractory multiple myeloma, early phase 1 data show.
Ribociclib Combo Produces Similar pCR to Chemo in HR+ Breast Cancer
Neoadjuvant ribociclib plus endocrine therapy showed pCR rates comparable to chemo in HR-positive, HER2-negative early breast cancer.
First-line Disitamab Vedotin/Toripalimab Ups Survival in HER2+ mUC
Disitamab vedotin with toripalimab improved PFS and OS over chemo in HER2-expressing metastatic urothelial carcinoma, per phase 3 trial interim analysis.
How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC
The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.
Ibrutinib/Nivolumab Yields Activity in Relapsed CNS Lymphoma
Three of 18 patients had remissions lasting over 2 years in a study of ibrutinib plus nivolumab for relapsed/refractory CNS lymphoma.
Retifanlimab Receives FDA Approval for Advanced Anal Cancer
Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.